AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory: Methylprednisolone helps reduce inflammation by suppressing the immune response and decreasing the production of inflammatory chemicals in the body. This can alleviate symptoms such as swelling, redness, and pain associated with conditions like arthritis, asthma, and allergic reactions.
Immunosuppression: Methylprednisolone suppresses the immune system's activity, which can be beneficial in autoimmune diseases like lupus, rheumatoid arthritis, and inflammatory bowel disease, where the immune system mistakenly attacks healthy tissues.
Allergic reactions: Methylprednisolone is often used to treat severe allergic reactions, such as anaphylaxis, by reducing inflammation and preventing the release of histamines and other substances that cause allergic symptoms.
Respiratory conditions: It can also be used to manage respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD) by reducing inflammation in the airways and making breathing easier.
Skin conditions: Methylprednisolone may be prescribed to treat various skin conditions such as eczema, psoriasis, and allergic dermatitis by reducing inflammation and suppressing the immune response in the skin.
Cancer treatment: In some cases, methylprednisolone is used as part of chemotherapy regimens to treat certain types of cancer, such as lymphoma and leukemia, to help reduce inflammation and manage side effects of cancer treatment.
Organ transplant: Methylprednisolone is often used as part of immunosuppressive therapy in organ transplant recipients to prevent organ rejection by suppressing the immune response and reducing inflammation.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 4.1 | 0.3 | 12.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2 | 0.4 |
| Allergies | 5.4 | 2.1 | 1.57 |
| Allergy to milk products | 1.2 | 1.6 | -0.33 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 4.2 | 4.3 | -0.02 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.4 | 4.75 |
| Ankylosing spondylitis | 2.8 | 0.6 | 3.67 |
| Anorexia Nervosa | 1.6 | 2.1 | -0.31 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 4.1 | 2.3 | 0.78 |
| Atherosclerosis | 1.3 | 1.2 | 0.08 |
| Atrial fibrillation | 2.6 | 1.6 | 0.63 |
| Autism | 6.2 | 5.5 | 0.13 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.8 | 0.8 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.6 | 2.3 | -2.83 |
| Carcinoma | 3.8 | 2.6 | 0.46 |
| Celiac Disease | 1.3 | 3.2 | -1.46 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 3.8 | 3.7 | 0.03 |
| Chronic Kidney Disease | 4.1 | 1 | 3.1 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.1 | -0.1 |
| Chronic Urticaria (Hives) | 1.5 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1.3 | 0.08 |
| Cognitive Function | 2.5 | 1.6 | 0.56 |
| Colorectal Cancer | 4.1 | 1.7 | 1.41 |
| Constipation | 1.2 | 0.7 | 0.71 |
| Coronary artery disease | 1.6 | 1.6 | 0 |
| COVID-19 | 7.5 | 7.1 | 0.06 |
| Crohn's Disease | 5.1 | 3.2 | 0.59 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.7 | 1.9 | -1.71 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 0.7 | 1.4 | -1 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 7.3 | 5.7 | 0.28 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 1.6 | -0.14 |
| Endometriosis | 2.7 | 1.5 | 0.8 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.2 | 1.3 | 0.69 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 2.6 | 1 | 1.6 |
| Functional constipation / chronic idiopathic constipation | 4 | 3 | 0.33 |
| gallstone disease (gsd) | 2.6 | 0.8 | 2.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 1 | -2.33 |
| Generalized anxiety disorder | 1.7 | 1.7 | 0 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.2 | 9.5 |
| Graves' disease | 1.9 | 3 | -0.58 |
| Gulf War Syndrome | 0.6 | 0.3 | 1 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.6 | 0.8 | 2.25 |
| Heart Failure | 2.8 | 1.3 | 1.15 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 1 | 0.6 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 1.6 | 1.1 | 0.45 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.5 | 3.6 | -0.03 |
| Hypothyroidism | 0.5 | 0.7 | -0.4 |
| Hypoxia | 2.6 | 0.3 | 7.67 |
| IgA nephropathy (IgAN) | 1.6 | 2.8 | -0.75 |
| Inflammatory Bowel Disease | 5.2 | 5.5 | -0.06 |
| Insomnia | 1.8 | 1.8 | 0 |
| Intelligence | 0.8 | 0.8 | |
| Intracranial aneurysms | 1.2 | 0.3 | 3 |
| Irritable Bowel Syndrome | 5.6 | 3.7 | 0.51 |
| ischemic stroke | 2.7 | 1.4 | 0.93 |
| Liver Cirrhosis | 5.8 | 2.9 | 1 |
| Long COVID | 4.1 | 5.9 | -0.44 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1.2 | 1 | 0.2 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.8 | 1.7 | -1.13 |
| ME/CFS without IBS | 1 | 1.6 | -0.6 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.5 | 3.2 |
| Metabolic Syndrome | 5.7 | 5.7 | 0 |
| Mood Disorders | 7.4 | 5.2 | 0.42 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 5.4 | 3.1 | 0.74 |
| Multiple system atrophy (MSA) | 0.4 | 0.7 | -0.75 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.3 | -6.67 |
| Neuropathy (all types) | 0.7 | 2 | -1.86 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.2 | 3.7 | 0.14 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 7.1 | 5.3 | 0.34 |
| obsessive-compulsive disorder | 4.4 | 2 | 1.2 |
| Osteoarthritis | 1.7 | 1.2 | 0.42 |
| Osteoporosis | 2.5 | 1.3 | 0.92 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 6.1 | 4.2 | 0.45 |
| Polycystic ovary syndrome | 4.3 | 2.7 | 0.59 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1 | 0.2 |
| Primary sclerosing cholangitis | 2.3 | 1.7 | 0.35 |
| Psoriasis | 2.5 | 1.3 | 0.92 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.9 | 2.9 | 1.03 |
| Rosacea | 0.8 | 0.7 | 0.14 |
| Schizophrenia | 5.3 | 2.5 | 1.12 |
| scoliosis | 0.1 | 0.3 | -2 |
| Sjögren syndrome | 2.7 | 2.5 | 0.08 |
| Sleep Apnea | 1.3 | 1.6 | -0.23 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.6 | 1 |
| Stress / posttraumatic stress disorder | 2.4 | 2.1 | 0.14 |
| Systemic Lupus Erythematosus | 3.3 | 2.2 | 0.5 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.7 | 3.5 | -0.3 |
| Type 2 Diabetes | 5.8 | 4.6 | 0.26 |
| Ulcerative colitis | 3.4 | 4 | -0.18 |
| Unhealthy Ageing | 2.8 | 1.6 | 0.75 |
| Vitiligo | 1.6 | 0.9 | 0.78 |
